Vanda Pharmaceuticals Inc.
$315.64M- Market cap
- $322.27M
- Debt
- +$78.23M
- Cash
- −$84.85M
Capital structure 80% equity / 20% debt · EV / Revenue 1.46x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: VNDA stock price vs ET: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ET's multiple
Needs ET P/S.
Implied fair value · at VNDA's multiple
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: VNDA FY 2025 (ended Dec 31, 2025) · ET FY 2025 (ended Dec 31, 2025).
Trendline
13 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Market cap plus debt, less cash.
Capital structure 80% equity / 20% debt · EV / Revenue 1.46x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
VANDA PHARMACEUTICALS INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
ENERGY TRANSFER LP · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.24x
1.39x
Net debt / EBITDA
Leverage against operating earnings
0.05x
3.93x
Cash and equivalents
Liquid reserves on the balance sheet
$84.85M
$1.27B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
SUPERNUS PHARMACEUTICALS, INC.
VNDA vs SUPN
CATALYST PHARMACEUTICALS, INC.
VNDA vs CPRX
Harmony Biosciences Holdings, Inc.
VNDA vs HRMY
ELI LILLY & Co
VNDA vs LLY
INCYTE CORP
VNDA vs INCY
Sarepta Therapeutics, Inc.
VNDA vs SRPT
ENTERPRISE PRODUCTS PARTNERS L.P.
VNDA vs EPD
KINDER MORGAN, INC.
VNDA vs KMI
WILLIAMS COMPANIES, INC.
VNDA vs WMB
ONEOK INC /NEW/
VNDA vs OKE
Targa Resources Corp.
VNDA vs TRGP
$78.23M
$68.36B
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.